Immuneering (NASDAQ: IMRX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Immuneering reported 0 open-market sales and 7 open-market purchases of 60,254 shares ($270,461), by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 23 June 2026 | Zeskind Benjamin J. | President and CEO | Open-market purchase | +2,400 | $4.56 | 2,315,252 | Form 4 |
| 15 June 2026 | Hall Brett Matthew | Chief Scientific Officer | Open-market purchase | +6,035 | $4.15 | 382,531 | Form 4 |
| 13 March 2026 | Neufeld Leah R | Chief People Officer | Grant or award | +3,628 | $4.29 | 29,598 | Form 4 |
| 16 January 2026 | Brakewood Harold Eugene | Chief Business Officer | Open-market purchase | +5,250 | $4.76 | 11,050 | Form 4 |
| 15 January 2026 | Schall Thomas J. | Director | Open-market purchase | +21,645 | $4.67 | 74,530 | Form 4 |
| 15 January 2026 | Hall Brett Matthew | Chief Scientific Officer | Open-market purchase | +2,298 | $4.57 | 376,496 | Form 4 |
| 13 January 2026 | Neufeld Leah R | Chief People Officer | Open-market purchase | +2,626 | $4.15 | 25,970 | Form 4 |
| 12 January 2026 | Feinberg Peter | Director | Open-market purchase | +20,000 | $4.35 | 135,441 | Form 4 |
| 3 October 2025 | Feinberg Peter | Director | Open-market purchase | +7,500 | $6.67 | 156,766 | Form 4 |
| 1 October 2025 | Bookman Michael | Chief Legal Officer, Secretary | Open-market purchase | +1,020 | $6.83 | 4,870 | Form 4 |
| 1 October 2025 | Neufeld Leah R | Chief People Officer | Open-market purchase | +800 | $6.38 | 23,344 | Form 4 |
| 1 October 2025 | Morales Mallory | Chief Accounting Officer | Open-market purchase | +300 | $6.39 | 27,533 | Form 4 |
| 30 September 2025 | Feinberg Peter | Director | Open-market purchase | +7,500 | $7.03 | 149,266 | Form 4 |
| 29 September 2025 | Feinberg Peter | Director | Open-market purchase | +5,000 | $7.18 | 141,766 | Form 4 |
| 15 September 2025 | Hall Brett Matthew | Chief Scientific Officer | Grant or award | +14,880 | $1.43 | 374,198 | Form 4 |
| 15 September 2025 | Morales Mallory | Chief Accounting Officer | Grant or award | +14,497 | $1.43 | 27,233 | Form 4 |
| 15 September 2025 | Neufeld Leah R | Chief People Officer | Grant or award | +11,815 | $1.43 | 22,544 | Form 4 |
| 2 July 2025 | Neufeld Leah R | Chief People Officer | Open-market purchase | +700 | $3.57 | 10,729 | Form 4 |
| 2 July 2025 | Hausman Diana | Director | Open-market purchase | +2,500 | $3.60 | 2,500 | Form 4 |
| 2 July 2025 | Hausman Diana | Director | Open-market purchase | +3,000 | $3.62 | 3,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Immuneering page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.